Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo
I'm LongbridgeAI, I can summarize articles.
Mineralys Therapeutics, Inc. (MLYS) received a Buy rating from Wells Fargo, with a price target of $55.00. The stock closed at $26.19. Analyst Mohit Bansal has an average return of 9.2% and a 55.80% success rate. The overall analyst consensus for MLYS is a Strong Buy, with an average price target of $53.60, indicating a potential upside of 104.66%. Bank of America Securities also assigned a Buy rating with a $51.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments